Streetbeat News

Products Services

AZN

AstraZeneca (NASDAQ:AZN) announced positive results from the ECHO Phase 3 trial of Calquence combined with bendamustine and rituximab in treating mantle cell lymphoma (MCL). The combination showed a significant improvement in progression-free survival (PFS) and a favorable trend in overall survival (OS) compared to standard chemoimmunotherapy. The data will be presented at the European Hematology Association 2024 Hybrid Congress.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 9:32 am

AAPL

GOOG

GOOGL

Google has introduced a new feature in its Chrome browser called 'Listen to this page,' which allows users to have webpages read aloud. This feature supports multiple languages and includes playback controls. It competes directly with Apple's Siri, which offers a similar feature in the Safari app.

Portfolio Pulse from Ananya Gairola

June 17, 2024 | 8:46 am

GRFS

Grifols' subsidiary Biotest has received FDA approval for Yimmugo, an intravenous immunoglobulin therapeutic for treating primary immunodeficiencies. The U.S. launch is expected in the second half of 2024. This approval marks the first U.S.-approved medicine in Biotest's portfolio and is expected to significantly contribute to Grifols' future sales and growth strategy.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 8:26 am

CART

Instacart and YouTube have announced a collaboration to make video ads shoppable, allowing consumers to purchase products directly from YouTube ads. This partnership represents a new extension of off-platform partnerships for both companies.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 8:00 am

JNJ

Johnson & Johnson's Phase 2 DAHLIAS study reveals that nipocalimab yields over 70% improvement in Sjögren's disease activity compared to placebo. This is significant as Sjögren's disease currently has no approved advanced treatments.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:55 am

RHHBY

Genentech's Phase III STARGLO study shows that Columvi, in combination with chemotherapy, significantly increases survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint with a 41% reduction in the risk of death. This treatment could offer a new option for patients ineligible for transplants.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:47 am

FEMY

Femasys Inc (NASDAQ:FEMY), a biomedical company focused on women's healthcare, is at an inflection point and expects growth potential following the overturn of Roe v. Wade. The company offers several products, including FemaSeed, FemVue, FemCath, and FemCerv, and is developing FemBloc, a non-surgical permanent birth control. CEO Kathy Lee-Sepsick highlights the company's undervaluation and significant market opportunities.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 7:22 am

AZN

AstraZeneca's CALQUENCE® (acalabrutinib) combination therapy shows a 27% decrease in progression or death risk in a Phase III study for mantle cell lymphoma, demonstrating significant improvement in progression-free survival and a favorable trend in overall survival compared to standard chemoimmunotherapy.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:21 am

PTPI

Petros Pharmaceuticals (NASDAQ: PTPI) aims to transition its prescription erectile dysfunction (ED) therapy, Stendra (avanafil), to over-the-counter (OTC) status. This move could significantly expand the ED market, potentially tripling its size. The company is leveraging its expertise in the Rx-to-OTC switch market and has aligned with the FDA for a pivotal study review in 2H 2024.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 7:08 am

HCM

HUTCHMED published Phase III results for Sovleplenib, showing a 48.4% response rate in ITP patients compared to 0% in the placebo group. The data supports a regulatory submission in China accepted in January 2024.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:04 am